These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31094083)

  • 1. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
    Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
    Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients.
    Kurk SA; Stellato RK; Peeters PHM; Dorresteijn B; Jourdan M; Oskam MJ; Punt CJA; Koopman M; May AM
    Am J Clin Nutr; 2019 Dec; 110(6):1395-1403. PubMed ID: 31515555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
    Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
    PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
    Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
    Nozawa H; Kawai K; Sasaki K; Murono K; Emoto S; Yokoyama Y; Abe S; Kishikawa J; Nagai Y; Sonoda H; Anzai H; Ozawa T; Ishihara S
    Int J Clin Pract; 2021 Nov; 75(11):e14863. PubMed ID: 34516723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
    Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
    Loree JM; Mulder KE; Ghosh S; Spratlin JL
    J Gastrointest Cancer; 2014 Jun; 45(2):154-60. PubMed ID: 24408272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
    Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
    BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
    Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
    Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
    Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer.
    Derksen JWG; Kurk SA; Oskam MJ; Peeters PHM; Punt CJA; Koopman M; May AM
    JNCI Cancer Spectr; 2019 Jun; 3(2):pkz014. PubMed ID: 31360897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
    Satram-Hoang S; Lee L; Yu S; Guduru SR; Gunuganti AR; Reyes C; McKenna E
    J Gastrointest Cancer; 2013 Mar; 44(1):79-88. PubMed ID: 23132351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
    Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
    Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.